Latest news

• The ADAPT Sepsis trial paper has recently been published in JAMA

  Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected SepsisThe ADAPT-Sepsis Randomized Clinical Trial

  Paul Dark, MD, PhD¹Link opens in a new windowLink opens in a new windowLink opens in a new window; Anower Hossain, PhD²Link opens in a new windowLink opens in a new windowLink opens in a new window; Daniel F. McAuley, MD^3,11Link opens in a new windowLink opens in a new windowLink opens in a new window; et al
  https://jamanetwork.com/journals/jama/fullarticle/2828036

Trial Summary

Sepsis is a common life-threatening condition that is triggered by infection. In sepsis, the body’s defence mechanisms (immune system) react excessively, resulting in widespread inflammation and swelling. If not treated quickly, sepsis can result in shutdown of vital organs which can result in death.

Each year in the UK, about 200,000 people develop sepsis and up to a quarter will die. Previous research indicates that early recognition of sepsis and rapid antibiotic treatments are the most important factors for patient survival. While starting antibiotics for sepsis is crucial, the recommended duration of such treatment is uncertain. The lack of research on when to stop treatment safely can lead to an overuse of antibiotics in this condition.

Antibiotic overuse is important because it promotes bacteria that are resistant to antibiotics (antimicrobial resistance), which means that sepsis and, indeed, other infections would become difficult to treat in the future. Shorter courses of antibiotics for a patient with sepsis, if given appropriately, may result in less antibiotic use resulting in fewer side effects, less risk of antibiotic resistance and a reduction in costs. Chemicals circulating in the blood can indicate the level of an infection and how effective the treatment of an infection is. These chemicals are called biomarkers. The two most well researched circulating biomarkers in sepsis are C-reactive protein (CRP) and procalcitonin (PCT). They are both protein chemicals produced by the human body in response to infection and can be readily measured in blood samples using NHS laboratory equipment.

The aim of this study is to find out whether the duration of antibiotic treatment given to patients with sepsis can be safely reduced following the close daily monitoring of these biomarkers. Patients will have blood samples taken daily whilst receiving antibiotic treatment (typically 7 days), follow-up at 28 & 90 days.

Trial Poster for patients and relatives

Patients recruited: 2,761

Sites Open: 28

 

Click here to view of list of sites.

Enquiries:

Please direct all enquiries to:

Uzma Manazar - Trial Manager
Tel: 02476 151 072
Email: adaptsepsistrial@warwick.ac.uk